DMK Pharmaceuticals Corporation (DMKPQ)

OTCMKTS · Delayed Price · Currency is USD
0.0001
+0.0001 (900.00%)
Oct 8, 2025, 3:39 PM EDT
900.00%
Market Cap101.00
Revenue (ttm)3.62M
Net Income (ttm)-22.41M
Shares Out10.09M
EPS (ttm)-6.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,704
Average Volume12
Open0.0001
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Beta32.15
RSI46.56
Earnings Daten/a

About DMK Pharmaceuticals

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other aller... [Read more]

Sector Healthcare
Employees 12
Stock Exchange OTCMKTS
Ticker Symbol DMKPQ
Full Company Profile

Financial Performance

In 2022, DMK Pharmaceuticals's revenue was $4.76 million, an increase of 115.34% compared to the previous year's $2.21 million. Losses were -$26.48 million, -42.22% less than in 2021.

Financial Statements

News

There is no news available yet.